US · SLP
Simulations Plus, Inc.
- Sector
- Healthcare · Medical - Healthcare Information Services
- Headquarters
- Lancaster, CA 93534-7059
- Website
- simulations-plus.com
Price · as of 2025-08-31
$14.91
Market cap 246.39M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $74.47 | +399.46% |
| Intrinsic Value(DCF) | $6.85 | -54.06% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $1.78 | $0.00 | |||
| 2012 | $0.00 | $3.07 | |||
| 2013 | |||||
| 2014 | $0.00 | $5.31 | |||
| 2015 | $0.00 | $14.89 | |||
| 2016 | |||||
| 2017 | $15.67 | $91.73 | $0.00 | $12.94 | |
| 2018 | $20.01 | $37.62 | $101.45 | $0.22 | $15.54 |
| 2019 | $32.40 | $43.46 | $39.50 | $0.41 | $10.84 |
| 2020 | $73.50 | $65.53 | $45.59 | $7.07 | $15.48 |
| 2021 | $53.40 | $53.89 | $34.66 | $6.47 | $9.48 |
| 2022 | $42.23 | $49.46 | $34.91 | $7.68 | $14.48 |
| 2023 | $35.50 | $44.27 | $9.53 | $6.41 | $9.06 |
| 2024 | $30.59 | $47.54 | $10.56 | $3.21 | $12.43 |
| 2025 | $17.13 | $74.47 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Simulations Plus, Inc.'s (SLP) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $74.47
- Current price
- $14.91
- AI upside
- +399.46%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$6.85
-54.06% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| SLP | Simulations Plus, Inc. | $14.91 | 246.39M | +399% | -54% | — | — | -5.32 | 2.76 | 4.35 | 21.26 | — | 6.64 | 58.38% | -89.33% | -81.74% | -42.13% | -51.50% | -38.12% | 0.00 | — | 7.67 | 6.98 | -2.06 | -75714.00% | 1309.00% | 3653.00% | 5.06% | 2.70 | 13.59% | 0.00% | 0.00% | 6.08% | -4.42 | 17.95 | 3.95 | 27.83 |
| ACIU | AC Immune S.A. | $2.93 | 294.76M | +1,817% | -50% | — | — | -3.77 | 1.71 | 7.03 | -0.66 | — | 3.10 | -129.12% | -191.80% | -186.44% | -37.31% | -787.64% | -24.61% | 0.05 | -393.82 | 1.71 | 1.65 | 0.63 | -2031.00% | 8451.00% | -20663.00% | 34.00% | 0.65 | 981.44% | 0.00% | 0.00% | 0.00% | -0.61 | 0.49 | 1.17 | -1.52 |
| AGL | Agilon Health, Inc. | $0.59 | 244.31M | +3,319% | +1,042% | — | — | -0.65 | 2.01 | 0.04 | 0.03 | -1.17 | 4.18 | -3.18% | -7.10% | -6.83% | -130.95% | 2821.09% | -26.04% | 0.15 | -63.41 | 1.02 | 0.89 | 0.42 | 5556.00% | -211.00% | 6755.00% | -46.67% | -0.10 | 797.30% | 0.00% | 0.00% | 2.97% | 0.03 | 0.09 | 0.00 | 1.55 |
| ANRO | Alto Neuroscience, Inc. | $19.69 | 611.7M | — | — | — | — | -1.42 | 0.58 | — | 0.93 | -1.67 | 0.58 | 0.00% | — | — | -153.99% | 95.25% | -46.51% | 0.11 | 49.90 | 16.92 | 16.81 | 2.20 | 8519.00% | — | 4594.00% | -56.68% | -4.74 | 68.72% | 0.00% | 0.00% | 90.14% | 0.93 | 1.29 | — | 0.72 |
| CLLS | Cellectis S.A. | $3.88 | 389.18M | +21,055% | +605% | — | — | -3.10 | 0.87 | 2.74 | 5.83 | — | 0.87 | 77.88% | -143.48% | -88.57% | -34.02% | 165.71% | -10.22% | 0.70 | -7.99 | 1.73 | 1.70 | 5.47 | -7684.00% | 539748.00% | -17562.00% | 17.18% | 0.13 | -54.33% | 0.00% | 0.00% | 0.12% | 0.93 | -2.83 | -1.33 | -0.96 |
| DH | Definitive Healthcare Cor… | $1.28 | 132.23M | +1,820% | +27% | — | — | -0.61 | 0.32 | 0.50 | 0.32 | — | -1.85 | 75.88% | -8.52% | -57.52% | -48.41% | -6.39% | -21.84% | 0.02 | -1.82 | 1.64 | 1.49 | 0.96 | -6328.00% | -424.00% | -1918.00% | 30.48% | 0.34 | 12.09% | 0.00% | 0.00% | 290.32% | 2.50 | -1.39 | -0.21 | 0.60 |
| KRRO | Korro Bio, Inc. | $12.13 | 114.23M | — | -2% | — | — | -2.38 | 1.24 | 87.71 | -1.33 | — | 1.24 | 100.00% | -4047.12% | -3680.36% | -50.61% | -158.39% | -37.32% | 0.28 | — | 8.79 | 8.54 | 0.12 | -8235.00% | — | 380.00% | -39.15% | -4.02 | -134.38% | 0.00% | 0.00% | 0.00% | -1.28 | -1.51 | 51.90 | -0.55 |
| NAKA | Nakamoto Inc. | $0.25 | 92.19M | +34,449% | +169% | — | +4,954% | -2.46 | 3.46 | 3.27 | -2.47 | -1.66 | 4.08 | 96.96% | -123.05% | -133.01% | -294.13% | -619.29% | -151.45% | 0.31 | -8.51 | 4.13 | 3.81 | 0.50 | 14815.00% | -2783.00% | 64918.00% | -39.07% | -5.07 | -643.12% | 0.00% | 0.00% | 18.24% | -2.21 | -2.13 | 2.72 | 0.21 |
| NRC | National Research Corpora… | $13.41 | 303.84M | +162% | -57% | — | -83% | 26.72 | 22.16 | 2.26 | 12.73 | — | -5.94 | 56.33% | 16.44% | 8.44% | 51.24% | 16.29% | 8.68% | 5.65 | 4.74 | 0.55 | 0.42 | 2.48 | -5000.00% | -396.00% | -1790.00% | 5.08% | 0.72 | 17.46% | 3.54% | 94.60% | 10.05% | 17.04 | 24.45 | 2.80 | 2.78 |
| OPRX | OptimizeRx Corporation | $7.58 | 141.3M | +1,777% | -62% | — | — | -4.17 | 0.72 | 0.91 | -11.65 | -61.30 | 136.67 | 64.45% | -14.88% | -21.83% | -16.51% | -9.57% | -11.34% | 0.28 | -2.23 | 2.89 | 2.77 | -2.23 | 680.00% | 2881.00% | -15890.00% | 5.70% | 0.26 | 3.34% | 0.00% | 0.00% | 4.86% | -7.56 | 21.69 | 1.12 | 0.76 |
| SOPH | SOPHiA GENETICS S.A. | $4.50 | 305.31M | +461% | -71% | — | — | -3.48 | 2.21 | 3.27 | -3.21 | — | 3.16 | 67.42% | -102.14% | -95.89% | -49.42% | -143.02% | -33.90% | 0.31 | -34.80 | 3.71 | 3.32 | 0.99 | -2213.00% | 449.00% | -1177.00% | -23.93% | -1.60 | -109.57% | 0.00% | 0.00% | 0.00% | -2.45 | -3.19 | 2.50 | -2.23 |
About Simulations Plus, Inc.
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, it provides population modeling and simulation contract research services; training and consulting services designed to accelerate pharmacometrics studies; and clinical-pharmacology-based consulting services in support of regulatory submissions. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
- CEO
- Shawn O'Connor
- Employees
- 243
- Beta
- 1.13
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($6.85 ÷ $14.91) − 1 = -54.06% (DCF, example).